Kubtec Celebrates Official Opening of their New Facility with Visit from Connecticut Governor Dannel Malloy

January 30, 2017 (Stratford, CT)-- Last week, Kubtec officially commenced operations at their new corporate and manufacturing headquarters in Stratford, Connecticut. Together with Guest of Honor, Connecticut Governor Dannel P. Malloy, Kubtec marked their relocation to larger facilities with an official ribbon cutting ceremony, performed by Governor Malloy, Vikram Butani, CEO of Kubtec, local Mayor John A. Harkins, and members of the Bridgeport Chamber of Commerce. Connecticut House Minority Leader Themis Klarides also attended the celebration.  Ms. Klarides has a special interest in breast cancer care, having been instrumental in driving legislation to mandate availability of 3-D mammography to women in Connecticut.Kubtec’s new address is 111 Research Drive, Stratford, CT 06615. Kubtec develops and manufactures innovative imaging products for clinical and research applications using digital X-ray technology as the core platform.  Particularly, the Kubtec Mozart® System uses proprietary 3-D Tomosynthesis technology to enable breast surgeons to obtain the clearest views of tumors while in the OR, enabling them to provide the best quality of care for their patients. Kubtec is focused on creating imaging solutions for Breast Care, Neonatal Care, and Pathology, in addition to applications for Forensic Science, Research, and Non-Destructive Testing. About Kubtec Kubtec, a registered trademark of KUB Technologies, Inc., offers the most innovative tools in digital x-ray equipment for specimen radiography, low-dose imaging, scientific research, forensic analysis, non-destructive testing, irradiation and more.  Kubtec is ISO 9001 and ISO 13485 certified and complies with U.S., Canadian, and European requirements for radiation safety.  Systems and manufacturer-trained support are available worldwide.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.